BMS grows immunology portfolio with IFM deal | August 21, 2017 Issue - Vol. 95 Issue 33 | Chemical & Engineering News
Volume 95 Issue 33 | p. 19 | Concentrates
Issue Date: August 21, 2017 | Web Date: August 20, 2017

BMS grows immunology portfolio with IFM deal

Department: Business
Keywords: mergers & acquisitions, immuno-oncology, STING agonists, innate immunity

Bristol-Myers Squibb will pay $300 million up front to acquire IFM Therapeutics, a developer of small-molecule drugs that target the innate immune system, the body’s first line of immunological defense. IFM investors could receive up to $1 billion more if the company’s lead molecules reach the market. BMS has been amassing immunology and immuno-oncology compounds, but they try to harness primarily the adaptive immune system. With this deal, BMS gains two preclinical cancer programs—NLRP3 agonists and STING agonists—intended to amp up innate immune response.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment